{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:02:46Z","timestamp":1791180166009,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary pulmonary hypertension is characterized by increased pulmonary vascular resistance and smooth muscle proliferation. Stable analogs are increasingly being used to treat this disease, although no data exists comparing their effects on proliferation. We therefore investigated the antiproliferative activity of several prostacyclin (PGI2) analogs on human pulmonary arterial smooth muscle cells, including UT-15 and iloprost, analogs that have recently completed successful clinical trials. Serum-induced proliferation, as assessed by [3H]thymidine incorporation (30 h) or cell number (48 h), was significantly inhibited with a 10-fold difference in potency, ranking in effectiveness UT-15 &amp;gt; iloprost &amp;gt; cicaprost &amp;gt; beraprost. Effects were reversed by the adenylyl cyclase inhibitor, 2,5\u2032 dideoxyadenosine (DDA) but not SQ22536. Intracellular cyclic AMP (cAMP) was elevated by all analogs and inhibited by DDA, although SQ22536 was a highly variable inhibitor, suggesting that different pathways might mediate cAMP generation. UT-15 produced a significantly larger and more sustained increase in cAMP compared with other analogs, with iloprost being the weakest elevator. Thus, PGI2 analogs potently inhibit proliferation of human pulmonary artery, probably via a cAMP-dependent pathway, although cAMP elevation in itself is not a good predictor of antiproliferative potency.<\/jats:p>","DOI":"10.1165\/ajrcmb.26.2.4695","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T21:09:08Z","timestamp":1365023348000},"page":"194-201","source":"Crossref","is-referenced-by-count":191,"title":["Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery"],"prefix":"10.1093","volume":"26","author":[{"given":"Lucie H.","family":"Clapp","sequence":"first","affiliation":[{"name":"Centre for Clinical Pharmacology, Department of Medicine, University College London, London, United Kingdom; and Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Finney","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology, Department of Medicine, University College London, London, United Kingdom; and Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Turcato","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology, Department of Medicine, University College London, London, United Kingdom; and Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Tran","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology, Department of Medicine, University College London, London, United Kingdom; and Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology, Department of Medicine, University College London, London, United Kingdom; and Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tinker","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology, Department of Medicine, University College London, London, United Kingdom; and Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2002,2,1]]},"reference":[{"key":"2026030623572671600_B1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(98)02111-4","article-title":"Primary pulmonary hypertension.","volume":"352","author":"Gaine","year":"1998","journal-title":"Lancet"},{"key":"2026030623572671600_B2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.","volume":"327","author":"Christman","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"2026030623572671600_B3","doi-asserted-by":"crossref","first-page":"208S","DOI":"10.1378\/chest.114.3_Supplement.208S","article-title":"Nitric oxide and endothelin-1 in pulmonary hypertension.","volume":"114","author":"Giaid","year":"1998","journal-title":"Chest"},{"key":"2026030623572671600_B4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"2026030623572671600_B5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group.","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"2026030623572671600_B6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)06784-5","article-title":"International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.","volume":"46","author":"Coleman","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"2026030623572671600_B7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structure, properties, and functions.","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol. Rev."},{"key":"2026030623572671600_B8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026030623572671600_B9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","article-title":"Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.","volume":"34","author":"Nagaya","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"2026030623572671600_B10","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.","volume":"342","author":"Hoeper","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"2026030623572671600_B11"},{"key":"2026030623572671600_B12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199243060-00008","article-title":"Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"2026030623572671600_B13"},{"key":"2026030623572671600_B14","first-page":"242","article-title":"Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells.","volume":"20","author":"Koh","year":"1993","journal-title":"Artery"},{"key":"2026030623572671600_B15","first-page":"85","article-title":"Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization.","volume":"45","author":"Grosser","year":"1995","journal-title":"Agents Actions Suppl"},{"key":"2026030623572671600_B16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0008-6363(99)00107-8","article-title":"Prostacyclin synthase gene transfer inhibits neointimal formation in rat balloon-injured arteries without bleeding complications.","volume":"43","author":"Harada","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"2026030623572671600_B17","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1161\/01.CIR.102.25.3130","article-title":"Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells.","volume":"102","author":"Wharton","year":"2000","journal-title":"Circulation"},{"key":"2026030623572671600_B18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0702383","article-title":"The effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cAMP elevation in isolated guinea-pig aorta.","volume":"126","author":"Turcato","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"2026030623572671600_B19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1165\/ajrcmb\/3.4.301","article-title":"Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers.","volume":"3","author":"Riva","year":"1990","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2026030623572671600_B20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0090-6980(91)90023-9","article-title":"U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells.","volume":"41","author":"Shirotani","year":"1991","journal-title":"Prostaglandins"},{"key":"2026030623572671600_B21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0021-9150(86)90002-X","article-title":"Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs: effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents.","volume":"60","author":"Orekhov","year":"1986","journal-title":"Atherosclerosis"},{"key":"2026030623572671600_B22","doi-asserted-by":"crossref","first-page":"C584","DOI":"10.1152\/ajpcell.1986.250.4.C584","article-title":"Effect of prostaglandin E1 on DNA synthesis in vascular smooth muscle cells.","volume":"250","author":"Owen","year":"1986","journal-title":"Am. J. Physiol."},{"key":"2026030623572671600_B23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0021-9150(84)90107-2","article-title":"Prostaglandin E1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor.","volume":"53","author":"Nilsson","year":"1984","journal-title":"Atherosclerosis"},{"key":"2026030623572671600_B24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1165\/ajrcmb.21.1.3502","article-title":"Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells: species variation.","volume":"21","author":"Jourdan","year":"1999","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2026030623572671600_B25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":"Altered pain perception and inflammatory response in mice lacking prostacyclin receptor.","volume":"388","author":"Murata","year":"1997","journal-title":"Nature"},{"key":"2026030623572671600_B26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-5381.1994.tb16997.x","article-title":"Potent contractile actions of prostanoid EP3 receptor agonists on human isolated pulmonary artery.","volume":"113","author":"Qian","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"2026030623572671600_B27","doi-asserted-by":"crossref","first-page":"8962","DOI":"10.1074\/jbc.272.14.8962","article-title":"Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3\u2032-polyphosphates.","volume":"272","author":"Johnson","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2026030623572671600_B28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0165-6147(99)01307-3","article-title":"G protein regulation of adenylate cyclase.","volume":"20","author":"Simonds","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"2026030623572671600_B29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1476-5381.1986.tb10196.x","article-title":"Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.","volume":"87","author":"Armstrong","year":"1986","journal-title":"Br. J. Pharmacol."},{"key":"2026030623572671600_B30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0090-6980(92)90093-9","article-title":"Comparison of iloprost, cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets.","volume":"43","author":"Ashby","year":"1992","journal-title":"Prostaglandins"},{"key":"2026030623572671600_B31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0090-6980(94)90030-2","article-title":"Inter-species extrapolation of pharmacokinetic data of three prostacyclin-mimetics.","volume":"48","author":"Hildebrand","year":"1994","journal-title":"Prostaglandins"},{"key":"2026030623572671600_B32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00002281-199305060-00015","article-title":"Treatment of systemic sclerosis.","volume":"5","author":"Pope","year":"1993","journal-title":"Curr. Opin. Rheumatol."},{"key":"2026030623572671600_B33","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1111\/j.1476-5381.1995.tb15943.x","article-title":"Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils.","volume":"116","author":"Armstrong","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"2026030623572671600_B34","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.","volume":"159","author":"Tuder","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026030623572671600_B35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1172\/JCI5911","article-title":"Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension.","volume":"103","author":"Geraci","year":"1999","journal-title":"J. Clin. Invest."},{"key":"2026030623572671600_B36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/01.CIR.18.4.533","article-title":"The pathology of hypertensive pulmonary vascular disease.","volume":"18","author":"Heath","year":"1958","journal-title":"Circulation"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/26\/2\/194\/67179826\/ajrcmb_26_2_194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/26\/2\/194\/67179826\/ajrcmb_26_2_194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:10:02Z","timestamp":1772860202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/26\/2\/194\/8501832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2002,2,1]]},"published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1165\/ajrcmb.26.2.4695","relation":{},"ISSN":["1044-1549","1535-4989"],"issn-type":[{"value":"1044-1549","type":"print"},{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,2]]},"published":{"date-parts":[[2002,2,1]]}}}